In the employment of serodiagnostic methods for the detection of orthoflavivirus infections, neutralization tests are known to be more accurate than measurements of antibody binding properties employing enzyme-linked immunosorbent assays. However, neutralization tests require infectious virus and laboratories with an appropriate level of biosafety. Single-round infectious particles (SRIPs), which encode a reporter gene instead of the viral structural protein genes, are replication incompetent and represent a safe and reliable alternative to the diagnosis of pathogenic viruses in neutralization tests. The orthoflavivirus SRIPs are produced by co-transfection of plasmids expressing virus-like particles and replicons into mammalian cell lines preferably with high transfection efficacy, such as HEK293T cells. However, certain orthoflavivirus SRIPs have limitations in their efficient expression at 37°C, which is the optimal temperature for mammalian cell growth, resulting in insufficient yields for neutralization tests. Here, we demonstrate that the production of orthoflavivirus SRIPs increases at the lower temperature of 28°C compared to 37°C. Moreover, infections with 28°C-cultured SRIPs in microneutralization tests were specifically inhibited in the presence of serum from mice infected with homologous viruses, suggesting that these SRIPs preserved their neutralizing epitopes for antibodies. Our method to produce high titer SRIPs is anticipated to promote efficient and safe SRIPs neutralization tests as a general serodiagnostic method for detecting virus-specific neutralizing antibodies against orthoflaviviruses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jviromet.2024.115007 | DOI Listing |
Transfusion
January 2025
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Background: The Association for the Advancement of Blood and Biotherapies guidelines recommend the use of high-titer COVID-19 convalescent plasma (CCP) for patients with SARS-CoV-2 at high risk of disease progression, including those who are immunocompromised. We hypothesized that conventional plasma units have comparable neutralizing antibody levels to CCP.
Study Design And Methods: Conventional plasma and CCP units were obtained from blood suppliers.
BMC Infect Dis
January 2025
WHO Regional Office for Europe, Marmorvej 51, Copenhagen, 2100, Denmark.
Background: Kyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional target of 0.5% was set for seroprevalence of hepatitis B surface antigen (HBsAg) among targeted birth cohorts.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid mutations relative to BA.
View Article and Find Full Text PDFSci Rep
January 2025
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
The ongoing emergence of SARS-CoV-2 variants, combined with antigen exposures from different waves and vaccinations, poses challenges in updating COVID-19 vaccine antigens. We collected 206 sera from individuals with vaccination-only, hybrid immunity, and single or repeated omicron post-vaccination infections (PVIs), including non-JN.1 and JN.
View Article and Find Full Text PDFViruses
December 2024
I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Background/objectives: The efficacy of monovalent BNT162b2 Omicron XBB.1.5 booster vaccination in liver transplant recipients (LTRs) has yet to be described, particularly regarding the immune response to emerging variants like JN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!